Keyword Index—Volumes 105–108 (2002)

Thrombosis Research 108 (2003) 365 – 371

Keyword Index—Volumes 105–108 (2002)

aIIbh3, 105:63 avh3, 105:79, 317 L-158,809, 105:531 (D-Ala7)-angiotensin I/II (1– 7), 105: 531 Abciximab, 106:25 Abdominal aortic aneurysm, 106:131 ABO blood groups, 108:195 ACE-inhibitors, 108:77 Acetylcholine, 105:507 Acetylsalicylic acid, 105:311 Actin, 108:133 Activated clotting time, 107:241 Activated partial thromboplastin time (aPTT), 105:463 Activated partial thromboplastin time, 105:455; 106:271 Activation, 106:105, 199 Activation markers, 105:241 Active and inactive isoforms, 106:157 Acute arterial occlusion, 106:285 Acute coronary syndromes, 106:275 Acute ischemic stroke, 107:223 Acute limb ischemia, 106:285 Acute myocardial infarction, 105:37, 193; 107:175, 223 Acute myocardial infarction, 107:175 ADAMTS13, 108:121 Adenosine, 105:71 Adenosine 3V:5V-cyclic monophosphate, 107:31 Adhesion, 108:57 Adenosine diphosphate, 107:45 Advanced glycation end products, 107:319 Afro-Brazilians, 105:519 Aggregation, 105:339 Aggregometry, 105:205 Aging, 107:1 AI/AN American Indian/Alaska Native, 108:273 Air –liquid interface, 108:215 AIS , acute ischemic stroke, 107:223 Alanine transaminase, 106:257

Alaska Native, 108:273 Alcohol ingestion, 105:147 Alpha 2-macroglobulin, 105:433 Alternative splicing, 105:63 Ambroxol, 105:71 American Indians, 108:273 Amino-terminal fragment of urokinase, 106:105 Amlodipine, 106:187 Angiogenesis, 106:81, 213 Angioplasty, 105:413 Angiotensin II, 105:531 Angiotensin-(1 –7) amino acid fragment, 105:531 Animal model, 106:165 Anionic phospholipid, 108:175 Ankle brachial index, 106:303 Ankle –brachial index, 107:115 Ankle –Branchial Index, 106:295 Annexin II, 106:63 Annexin V, 107:345 Anti-heparin-PF4 antibodies, 108:49 Anti-heparin-platelet factor 4 antibodies, 106:149 Anti-phospholipid antibodies, 105: 177 a2-Antiplasmin, 105:247, 263 Anti-Xa, 107:235 Anti-Xa activity, 106:179 Antibodies, 105:401; 107:135 Antibody subtypes/isotypes, 105:117; 106:149 Anticoagulant, 105:303, 347; 107:351 Anticoagulant activity, 105:183, 455; 106:51; 108:1 Anticoagulant therapy, 107:277 Anticoagulants, 105:103, 353; 106: 275; 107:241 Anticoagulation, 108:3, 85 Antifactor Xa, 105:201 Antiheparin – platelet factor 4 antibodies, 105:117 Antioxidative, 108:317 Antiphospholipid antibody syndrome, 105:513

0049-3848/03/$ - see front matter D 2003 Elsevier Science Ltd. All rights reserved. doi:10.1016/S0049-3848(03)00173-7

Antiplatelet therapy, 108:37 Antithrombin III, 105:183; 107:223 Antithrombin, 105:419, 537; 106:157 Antithrombotic, 106:267 Antithrombotic therapy, 107:1 Antithrombotics, 107:357 APC cofactor activity, 105:233 APC resistance, 106:59 Apoptosis, 107:345 APPT activated partial thromboplastin time, 105:277 Aprotinin, 107:17; 108:161 APTT, 107:235 Argatroban, 105:401 Arm exercise, 108:297 Arsenic trioxide, 106:63 Arsenite, 105:55 Arterial hemorrhage, 108:335, 341 Artery, 106:249 Artificial materials, 105:407 Asn-linked glycan, 105:95 Aspirin, 105:209, 385; 106:19; 107:39, 45; 108:43, 303 Aspirin non-response, 108:37 Aspirin resistance, 107:45; 108:37, 115 Atherosclerosis, 105:87, 291, 419; 106:205, 295, 243; 303; 107:115, 189; 108:67, 195, 209 Atorvastatin, 105:285 Atrial fibrillation, 106:269; 107:1; 108:1, 3 Atroxin, 105:3 Autoantibody, 107:175 BAB drugs h-adrenoceptorblocking drugs, 105:339 Bacteriophage M13 genetics, 107:365 Bedside test, 108:91 Behcßet’s disease, 105:125; 106:19 Berberine, 106:223 Beta-thromboglobulin, 105:147

366

Biomaterial, 108:57 Biosensor chips, 105:87 Bleeding, 106:63 Bleeding time, 105:311 h-Blockers, 105:339 Blood coagulation, 107:255; 108:323 Blood coagulation tests, 105:165 Blood collection systems, 108:85 Blood compatibility, 105:407 Blood platelet, 107:141 Blood platelets, 105:165, 339; 106:143 Blood rheology, 107:101 Body weight, 105:201 Bone, 105:353 Bradykinin, 106:41 Brain, 105:447 C1, 105:537 CA repeat polymorphism, 105:271 CABG coronary artery bypass grafting, 107:189 CAD cationic amphiphilic drugs, 105:339 Caesarian section, 105:15 Calibration, 105:499 Cancer, 106:127 Carbohydrate, 105:247 Cardiopulmonary bypass, 105:523; 108:161 Cardiovascular events, 106:295 Cardiovascular risk, 108:287 Carrier diagnosis, 105:271 Caspase, 107:217 Catheter-direct thrombolysis, 106:285 CBS 844ins68, 107:13 CCP complement control protein, 108:175 CD40 ligand, 108:311 CD40L, 106:35 CD40L CD40 ligand, 108:311 CD62, 107:201 Cell adhesion, 106:243 Cell adhesion molecules, 107:121 CEPI PFA with test cartridge collagen/epinephrine, 105:205, 217 Cerebrovascular diseases, 105:299 Ceruloplasmin, 105:419 g-Chain, 107:157 Chloroquine, 105:339 CHO Chinese hamster ovary, 105:63 Chronic ITP, 107:135 Chronic renal failure, 105:299 Chylomicrons, 105:419

Keyword Index / Thrombosis Research 108 (2003) 365–371

CI 95% confidence interval, 105:493 Circulating lymphocyte, 31:31 Claudication, 106:303 Clinical examination, 105:43 Clopidogrel, 105:173, 209; 107:39 Clot retraction, 108:161, 181 Clotting rate, 105:499 Co-transfection, 107:157 Coagulant factor V gene Leiden mutation, 106:7 Coagulation, 105:125, 193, 257, 285, 481; 106:81, 257 107:245; 108:19, 215 Coagulation and fibrinolytic system, 108:191 Coagulation factor X, 106:71 Coagulation factors, 105:183; 107:223 Coagulation inhibitors, 105:15 Cocoa flavonoids, 106:191 Collagen, 105:153 Complement, 105:441 Competitive RT-PCR, 105:217 Congenital dysplasminogenaemia, 105:513 Contact activation system, 105:407 Contact phase system, 105:463 Cord and adult plasma, 105:433 Coronary angioplasty, 108:43 Coronary artery, 108:115 Coronary artery bypass surgery, 108:195 Coronary artery disease, 105:299; 107:55, 189; 108:195 Coronary disease, 105:493 Coronary heart disease, 105:25, 285; 106:137 Counts, 106:31 CRP, 105:379 CSF, 105:447 CSGE, 107:51 Cut-off, 107:181 CVI within-subject variation, 107:263 CV coefficient of variation, 107:181 CV coefficients of variation, 105:177 Cyclic AMP, 105:71 Cyclic GMP, 105:71 Cyclooxygenase, 106:223 Cytokines, 108:77 Cytosolic phospholipase A2, 105:339 D-dimer, 105:257, 43; 107:1, 151, 197; 108:107 Dalteparin, 11:13 DD D-Dimer, 108:19

DDI, 107:7 Deep vein thrombosis, 105:241, 371; 106:97, 183; 107:85, 93, 163 Deep venous thrombosis, 105:49, 477; 106:13, 121; 107:101, 197; 108:203 Deep-vein thrombosis, 105:43 Dementia, 107:337 Denaturation, 105:499 Dermatan sulfate, 107:67 Detection of mutation, 107:51 Dexamethasone, 108:303 DGGE denaturing gradient gel electrophoresis, 105:271 Diabetes, 105:379; 107:217; 108:151 Diabetes mellitus, 106:91; 107:319 Diagnosis, 107:197 Diallyl sulphides, 108:317 Dialysis, 107:351 Different time periods, 107:277 Diltiazem, 106:187 Dilute prothrombin time, 105:177 Dipyridamole, 105:71 Direct thrombin inhibitor, 105:371; 107:163 Disintegrin, 105:79 Disseminated intravascular coagulation, 108:329 Disseminated intravascular coagulation, 107:357 Distribution, 105:447 DIT dithiaden, 105:339 Divalent cations, 105:537 DNA polymorphisms, 105:519 DVT, 107:13 DX-9065A, 106:267 Dysfibrinogenemia, 107:157 E-selectin, 106:243 Ecarin clotting time, 106:271 Economy class syndrome, 108:19 ECs endothelial cells, 105:161 EGTA ethylene glycol bis(h-aminoethyl ether)-N,N,NV,NV-tetraacetic acid, 108:133 Electronic microscopy, 107:75 ELISA enzyme-linked immunoadsorbent assay, 108:329 Embolectomy, 106:285 Embolization, 108:245 Endogenous thrombolysis, 106:165 Endometrial cell, 108:235 h3-Endonexin, 105:63 Endoplasmic reticulum, 108:221 Endothelial cell damage, 105:291

Keyword Index / Thrombosis Research 108 (2003) 365–371

Endothelial cell proliferation, 105:79 Endothelial cell, 106:213 Endothelial cells, 105:317; 106:205, 237, 243; 107:329; 108:77 Endothelial differentiation gene, 108:169 Endothelial function, 108:249 Endothelial nitric oxide synthase gene, 107:129 Endothelium, 105:125; 106:81 Endotoxin, 108:347 Enoxaparin, 105:201, 225 EPCR 4031ins23, 107:13 Epidemiology, 106:97 Epinephrine, 107:147 Eptifibatide, 106:25 Erythrocyte aggregation, 105:487 Erythrocyte membrane, 108:317 Ethamsylate, 107:329 Ethnic groups, 105:519 Euro-Brazilians, 105:519 Exercise test, 105:481 Exercise, 105:147; 108:115, 147 Experimental, 108:215 Experimental model, 105:209 F factor, 107:163 FACS fluorescence-activated cell sorting, 2083:303 Factor V G1691A, 107:13 Factor V Leiden mutation, 106:183, 265 Factor V Leiden, 105:15; 107:181, 7 Factor VII, 105:493; 107:223; 108:329 Factor VIII antibody, 107:291 Factor VIII gene, 105:271 Factor VIII, 105:87; 107:223; 107:291; 108:195 Factor X deficiency, 107:51 Factor Xa inhibition, 106:267 Factor Xa inhibitor, 105:347 Factor Xa –TFPI complex, 105:33 Factor Xa, 106:165; 106:81; 107:351 Factor XI, 107:55 Factor XII autoactivation, 105:463 Factor XII deficiency, 106:265 Factor XIII, 105:263 Family – generation, 105:109 N-Fatty acids, 105:139 FDP fibrinogen degradation product, 106:285 FGF-2, 106:213 Fibrin complexes, 105:3 Fibrin dressing, 108:335, 108:341 Fibrin formation, 105:407

Fibrin generation, 108:323 Fibrin glue, 107:245 Fibrin network structure, 107:75 Fibrin networks, 107:263 Fibrin specificity, 106:113 Fibrin, 105:3; 107:151 Fibrinogen, 105:3, 379, 419, 487, 499; 106:89; 108:245, 287, 335, 341; 107:121, 303 Fibrinolysis, 105:55, 125, 193, 247, 257, 263, 285, 359, 481; 106:165; 107:17; 108:19, 235 Fibronectin, 105:37 FII prothrombin, 107:223 Fish oil, 105:311 Flaveria bidentis, 105:183 Flow chamber, 107:39 Flow cytometry, 105:205, 217, 385; 106:171, 91; 108:139, 291, 43 Folates, 105:109 Fondaparinux, 107:241 Freeze-drying, 105:499; 107:263 Frequency, 106:97 Frozen storage, 107:263 Fucansulfate, 105:455 Fucoidan, 106:213 FV Leiden, 106:59 FXIII, 105:317 G20210A prothrombin gene mutation, 107:7 Galectin, 108:257 GAM IgG goat antimouse IgG, 105:331 Gamma-carboxylase, 108:221 Gangrene, 106:303 GAPDH glyceraldehyde-3-phosphate dehydrogenase, 107:169 Gastrointestinal lymph, 105:419 Gel permeation chromatography, 105:303 Gene mutations, 107:109 Gene polymorphism, 106:131 Gene, 106:89 Genetics, 105:519 Ginkgo biloba, 108:151 Gla residues, 108:221 Global assay, 107:181 Glycine, 107:255 Glycoaminoglycan, 107:67 h2-glycoprotein I, 108:175 Glycoprotein IIb/IIIa, 107:303 Glycoprotein IIIa, 105:331 GP IIb – IIIa, 105:79 GP IIb/IIIa antagonists, 106:35; 108:181

367

GP IIb/IIIa receptor antagonists, 106:35, 149 GP IIb/IIIa, 108:181 GpIIb –IIIa, 108:57 GPIIb/IIIa complex, 106:191 GPIIb/IIIa, 105:317 GPIIb/IIIa Glycoprotein IIb/IIIa, 2083:303 GPRphoresis, 105:3 a-Granule secretion, 106:229; 107:23 Graphical models, 105:109 GT dinucleotide repeats, 106:131 Guanosine 3V:5V-cyclic monophosphate, 107:31 H1-histamine antagonists, 105:339 Haematological malignancies, 105:33 Haemophilia A, 105:271; 107:291 Haemostasis activation markers, 108:107 Haptoglobin, 105:419 Heart valve thrombosis, 107:39 Helicobacter pylori, 108:245 Helium – neon laser, 105:507 Heme oxygenase-1, 106:131 Hemorrhage, 105:523 Hemorrhagic tendency, 105:277 Hemostasis, 105:165, 329 Hemostatic efficacy, 105:139 Heparin affinity chromatography, 106:157 Heparin cofactor II, 105:183; 106:51; 107:67 Heparin surface, 105:407 Heparin, 105:359, 419, 537; 106:213; 107:67, 351; 108:91, 97, 161, 291, 303 Heparin-derived oligosaccharide, 105:303 Heparin-derived oligosaccharides, 105:447 Heparin-induced thrombocytopenia, 108:49 Heparin-induced thrombocytopenia, 105:401 Hepatocyte, 107:169 Hepatocytes proliferation, 106:257 Heterodimer, 107:157 Hirudin, 105:401; 106:271 HIT syndrome, 105:117; 106:149 Homocysteine, 105:109, 503; 106:19, 121; 107:79, 189; 108:127 Homozygous prothrombin A20210A mutation, 105:49 Hormone replacement therapy, 105:291

368

Hospitalization, 108:273 HS hypertonic saline, 107:255 5HT 5-hydroxytryptamine, 108:303 Human aortic smooth muscle cell, 107:271 Human microvascular endothelial cells (HMEC-1), 105:55 Human platelets, 105:385 Human umbilical endothelial cells, 105:531 Human umbilical vein endothelial cells (HUVECs), 105:161 Humic acid, 108:67 5-Hydroxytryptamine, 108:303 Hypercoagulable, 106:269 Hyperhomocysteinemia, 105:299; 106:121; 2079:229 Hypertension, 105:507 Hypertensive complications, 105:19 Hypertonic saline, 107:255 I-domain, 105:153 I-kappa B alpha (I-nBa), 106:199 Immune tolerance, 107:291 Immunogenicity, 105:401 Immunohistochemistry, 107:189 Impairment, 107:147 In vitro assay, 107:75 In vitro closure time, 105:205 Indirect genetic diagnosis, 105:271 Inflammation, 106:257; 107:329; 108:245, 249 Inherited bleeding disorder, 105:135 INR, 107:61; 108:85 INR international normalized ratio, 105:353 Instrument, 107:181 Insulin aspart, 107:31 Insulin, 106:91; 107:209, 107:31 a2h1 Integrin, 105:153 Integrin activation, 105:63 Intensive care, 105:201 Interactions, 105:537 Intermittent Claudication, 106:295 International normalized ratio, 107:277 Intima media thickness, 105:291 Intima-media thickness, 107:115 Intracellular calcium, 107:201 Intracerebral hemorrhage, 108:31 Intracranial hemorrhage, 108:25 Ischemia, 108:249 Ischemic stroke, 106:171; 108:63 ISI, 107:61 ITP, 107:337 JTV-803, 107:351

Keyword Index / Thrombosis Research 108 (2003) 365–371

Kallikrein, 108:257 KGD Lys– Gly– Asp, 105:79 Korea, 107:79, 129 L-selectin, 106:1 Laboratory method, 108:323 Laser, 108:245 Latent antithrombin, 106:157 LDL low-density lipoprotein, 107:189 Left ventricular thrombus, 105:37 Leiden factor V R506Q mutation, 108:323 Lepirudin, 108:91 Leukocytes, 107:209 Leukocytes, 107:121 Lipids, 105:311 Lipopolysaccharide, 108:303 Lipoprotein (a), 105:49 Lipoprotein(a), 105:19 Lipoproteins, 105:87 Liver, 107:169 Liver clearance, 108:257 Liver injury, 106:257 Liver repair, 106:257 LMW heparin, 105:193 Location, 106:97 Low molecular weight heparin, 108:197 Low molecular weight heparin, 108:291 Low-molecular weight dextran sulfate, 105:441 Low-molecular weight heparin, 105:241; 107:241 Low-molecular-weight heparin, 105:225; 106:13; 108:49, 97 Lower extremity ischemia, 105:379 LPS, 107:141 Lupus anticoagulants, 105:177 Lupus ratio test, 105:177 Lysophospholipid, 108:169 Macrophages, 108:227 Malignant tumor, 105:471 Mast cells, 105:359 Mechanical heart valve, 108:3 Mechanical heart valves, 107:39 Medicinal plants, 106:51 Melagatran, 105:371; 107:163 Memory disorder, 107:337 Meningococcal disease, 108:347 Menstrual cycle, 108:147 Messenger RNA, 106:237 Metal-dependent proteases, 106:229; 107:23

Metalloprotease, 108:121 Methionine, 105:503 Methylenetetrahydrofolate reductase, 108:127 Microparticle generation, 105:117 Microparticle, 108:215 Migration, 107:271 Minimum centres, 107:61 Missense mutations, 105:233 MODS, 105:201 Monoclonal antibody, 107:151 Monocytes, 106:243; 108:77 MTHFR gene C677T mutation, 106:7 MTHFR TT677, 107:13 MTHFR, 105:109 Multiple myeloma, 105:277 Myeloproliferative syndromes, 108:139 Myocardial infarction, 105:481, 487, 493; 106:113, 137; 108:191 N-Glycosylation site mutant, 105:95 Nadroparin, 106:179 Neoantigenic determinant, 107:151 Neonates, 107:17; 105:247 Neutrophils, 108:67; 106:1 Nifedipine, 106:187 Nitric oxide (NO), 105:507; 106:41 Nitric oxide synthase, 105:71 Nitric oxide, 105:71; 107:31 Nuclear factor-kappa B (NF-nB), 106:199 Nuclear localization signal, 105:63 Obese patients, 106:179 Obesity, 108:203 Oestrogen, 108:303 Oral anticoagulants, 108:31 Oral direct thrombin inhibitor, 107:93 Orbofiban, 106:35 Orthopaedics, 105:371 Orthopedic surgery, 108:49 Osteoporosis, 105:353 Ovarian steroids, 108:235 Oxidation stress of platelets, 105:325 Oxidative stress, 105:277; 106:143 oxLDL, 107:175 P-selectin expression, 105:117 P-selectin, 106:191; 107:329, 303; 108:37, 107 Patient care management, 105:103 Patent foramen ovale, 105:189 Patient self-management, 106:101 PCR – SSCP, 107:109

Keyword Index / Thrombosis Research 108 (2003) 365–371

Pentasaccharide, 106:267 Peptide fragments, 106:81 Peptide, 105:263 Percutaneous coronary intervention, 105:385 Percutaneous coronary interventions, 107:241 Peripheral Arterial Disease, 106:295 Peripheral arterial disease, 106:303 Peroxisomal proliferator activated receptor-g, 108:227 Persistent risk factors, 107:101 PFA-100 analyzer, 105:385 PFA-100R, 107:45; 108:115 PFA-100k, 108:43 PFA-100, 105:441; 108:37 Phage display system, 105:365 Phage display, 105:331 Pharmacodynamics, 105:225, 447, 455 Pharmacokinetics, 105:225 Phosphatidylinositol-3-kinase, 107:31 Phosphatidylserine, 107:345 Phospholipid metabolism, 106:223 Phospholipid surface, 105:87 Phosphorylation, 106:199 Pig, 107:351 PLA1/A2 polymorphism, 108:63 Plant polysaccharides, 106:51 Plasma nitric oxide level, 107:129 Plasma procarboxypeptidase B, 106:59 Plasmatic clots, 107:75 Plasmin, 105:247; 106:105; 107:17, 169 Plasminogen activator inhibitor, 108:235 Plasminogen activator inhibitor-1 (PAI-1), 105:161; 106:41 Plasminogen activator inhibitor-1, 105:531 Plasminogen activator inhibitor-type 1, 107:115 Plasminogen activator tissue-type, 108:257 Plasminogen activator, 108:235 Plasminogen activators, 105:487 Plasminogen Tochigi, 105:513 Plasminogen, 105:263, 247; 106:105; 106:63 Plasmon resonance, 105:87 Plaster cast, 105:477 Platelet activation, 105:117, 165; 106:149, 191, 229; 107:23, 337; 108:49, 133, 139 Platelet adhesion receptors, 105:523

Platelet adhesion, 105:173; 107:141 Platelet aggregability, 107:147 Platelet aggregation inhibitors, 105:165; 107:121 Platelet aggregation, 105:79, 147, 311, 441, 523; 106:187, 191, 223, 35; 107:135, 201, 319; 108:147, 151, 317; 11:223 Platelet aggregometry, 107:325 Platelet contractile force, 105:523; 108:161 Platelet count, 105:147 Platelet dysfunction, 108:161 Platelet function, 105:139; 106:191; 108:297 Platelet glycoprotein receptor IIb/IIIa, 108:63 Platelet hyperaggregability, 107:325 Platelet microparticles (PMP), 107:217 Platelet microparticles, 107:337 Platelet procoagulant activity, 105:165 Platelet reactivity, 107:45 Platelet transfusion, 107:345 Platelet – leukocyte conjugates, 108:139 Platelet – leukocyte interaction, 107:209 Platelet, 105:153; 106:25, 137; 107:345; 108:169, 215, 311 Platelet-derived growth factors, 105:173 Platelets, 105:71, 173, 205, 217, 277, 317, 331, 413, 503; 106:91, 199; 107:1, 31, 209, 217, 255, 329; 108:43, 57, 181, 291, 303, 43; 107:303 PLG plasminogen, 105:513 PLT platelet count, 11:357 pNA para-nitroanilide, 105:263 Point of care monitoring, 108:91 Polyacrylmide gel electrophoresis, 105:303 Polymorphism, 105:493; 106:25, 89; 107:129; 108:127 4G/5G-polymorphism, 107:115 PoPK Porcine pancreatic kallikrein, 108:257 Post-exercise recovery, 105:147 Post-thrombotic syndrome, 108:279 Postmenopause, 107:229 Postprandial lipids, 105:419 PPACK D-Phe-Pro-Arg-CH2Cl2, 107:365 Pre-test clinical probability, 108:107 Preeclampsia, 105:19

369

Pregnancy loss, 108:197 Pregnancy, 105:19, 257; 107:85; 108:97; 106:13 Preincubation time, 105:463 Prekallikrein autoactivation, 105:463 Prekallikrein deficiency, 105:463 Pro proline, 11:109 Procarboxypeptidase U, 106:59 Procoagulatory effects, 106:113 Profibrin, 105:3 Prognosis, 106:89 Proinsulin C-peptide, 106:91 Prokaryotic expression, 105:331 Prophylaxis, 105:477; 108:97 Propyl gallate, 108:335 Prostacyclin, 108:151; 106:223; 107:175 Prostaglandins, 108:249 Protease activated receptor-2, 107:271 Protease, 106:127 Protease-inhibitory activity, 105:95 Protein C anticoagulant pathway, 107:109 Protein C inhibitor, 105:95; 107:67 Protein C, 105:433; 107:181 Protein factor of neutrophil supernatant, 107:201 Protein S deficiency, 105:49 Protein S, 105:233, 433; 108:209, 323 Protein Z, 106:183, 269 Protein Z-dependent protease inhibitor (ZPI), 106:183 Proteolysis, 108:121 Prothrombin activation, 105:433; 106:257 Prothrombin complex concentrate, 108:25 Prothrombin G20210A mutation, 107:13 Prothrombin gene G20210A mutation, 106:7 Prothrombin time, 105:543; 107:61 Prothrombin, 106:81; 108:209 PUFA polyunsaturated fatty acid, 108:209 Pulmonary embolism, 105:49, 106:89, 121; 107:85, 93 Pulmonary thromboembolism, 106:7 PV polycythemia vera, 108:139 PVB19 parvovirus B19, 105:391 Quality control, 105:543 Quality of health care, 105:103 Quality of oral anticoagulation, 106:101

370

Rabbit model, 105:139 Rabbit, 106:71 Rabbits, 108:329 Radiographic contrast agent, 105:413 Radiolabeling, 105:303 Randomised controlled trial, 108:91 Rat globin, 107:201 Rat, 107:163 Receptor-mediated endocytosis, 108:257 Recombinant fibrinogen, 107:157 Recombinant fusion proteins, 107:365 Recombinant granulocyte colony-stimulating factor (rGCSF), 105:161 Recombinant granulocyte – macrophage colony-stimulating factor (rGM-CSF), 105:161 Recombinant hirudin, 108:91 Recombinant human erythropoietin (rHuEPO), 105:161 Recombinant tissue thromboplastin, 105:177 Recurrence, 108:203 Recurrent thromboembolism, 107:101 Release, 106:249 Renal impairment, 105:225 Renal insufficiency, 105:277 Reperfusion, 108:249 Restriction fragment length polymorphisms, 105:271 Resveratrol, 106:143; 205, 243; 107:141 Reticulated platelet, 106:171 Retinoic acid, 106:63 Risk factors, 106:295; 108:63 ROC receiver operating characteristic, 108:107 ROTEG rotation thrombelastography, 108:19 Routine coagulation tests, 105:441 Roxifiban, 106:35; 107:303 %RPC percent residual platelet count, 105:139 S/D solvent/detergent, 105:391 S saline formulation, 105:371 Salmon, 107:245 Saturated fat, 108:209 Screening, 107:181 Seasonal variation, 106:97 Secondary prophylaxis, 108:37 Secretion, 105:233 Semifibrin, 105:3

Keyword Index / Thrombosis Research 108 (2003) 365–371

Semotiadil, 106:187 Sepsis, 108:347 Serine protease, 107:67 Serotonin, 107:319 Serpin, 107:67 Serum, 105:257 Shear rate, 108:297 Shear stress, 108:121; 108:311 Sialic acid, 106:137 Simvastatin, 105:285 Single-chain Fv fragment, 105:331 Single-chain urokinase, 106:105 SIOPA, 105:325 SLE, 105:513 SM skimmed milk, 106:365 Smoking, 106:1 Smooth muscle cell migration, 105:79 Smooth muscle cells, 105:173 Snake venom, 105:153 SNP single nucleotide polymorphism, 105:519 Solid tumours, 105:33 Soluble thrombomodulin, 105:291 Sphingosine 1-phosphate, 108:169 Splenectomy, 107:337 Stability, 107:263 Standardization, 108:85 Statins, 108:77 Statistics, 107:229 Stem cell factor, 105:359 Stent, 105:209 sTF soluble tissue factor, 105:285 Sticky-platelet syndrome, 107:325 Stroke, 105:189; 107:287 Stroke-prone spontaneously hypertensive rat (SHRSP), 105:507 Subclavian, 108:279 Subcutaneous absorption, 105:455 Sulphated flavonoids, 105:183 Surgery, 108:3 Surgical sealant, 107:245 Swimming, 108:191 Swine, 108:335; 341 tmax time at which maximum melagatran concentration occurred, 2067:93 h-thromboglobulin, 106:229 h-Thromboglobulin, 107:23 t-PA, 106:249 T2DM Type 2 diabetes mellitus, 108:151 TAFI activity, 106:59 TAT, 107:7 Taxol, 108:133 TBS Tris-buffered saline, 11:365

TFPI , 105:1, 33; 108:347 TFPI-1 , 105:217 TFPI-2 , 105:217 The expression of GpIb receptors, 105:325 Theonezolide A, 108:133 Therapeutic range, 107:235 Thiazole orange, 106:171 Thiazolidinediones, 108:227 Thioglycosides, 107:357 Thrombapheresis, 107:147 Thrombelastography, 108:19 Thrombin antagonists and inhibitors, 107:365 Thrombin potential, 105:433 Thrombin, 105:3, 503; 106:165, 275; 107:67, 217, 245, 365; 108:323 Thrombocytopenia, 108:291 Thromboembolism, 108:191 Thrombolysis, 105:193; 106:113; 108:279 Thrombolytic therapy, 106:285 Thrombomodulin, 105:25; 107:109; 108:227 Thrombophilia, 105:125; 106:183; 107:55, 229; 108:197; 108:323 Thrombosis animal model, 107:163 Thrombosis, 105:233, 299, 359, 413, 507; 106:19, 71, 275, 319; 108:127, 279 Thrombotic microangiopathy, 106:127 Thromboxane A2, 106:223; 108:147, 297 Thromboxane, 107:175; 108:151 Thrombus formation, 105:209 Thrombus regression, 108:203 Thrombus, 106:137 Thrombus, 108:245 TI therapeutic interval, 105:103 Ticlopidin, 108:43 Tirofiban, 106:25 Tissue factor (TF), 106:41 Tissue factor pathway inhibitor, 107:223 Tissue factor, 105:217; 106:205; 107:223; 108:77, 227 Tissue factor/factor VIIa complex, 107:271 Tissue plasminogen activator, 105:25 Tissue plasminogen activator, 105:359 TM 4– 6 thrombomodulin fragment containing epidermal growth factor-like domains 4 – 6, 107:67

Keyword Index / Thrombosis Research 108 (2003) 365–371

tPA tissue-type plasminogen activator, 107:169 Transcobalamin, 108:127 Transcription, 106:237 Transient risk factors, 107:101 TRAP thrombin receptor-activating peptide, 2083:303 Travel thrombosis, 108:19 Treatment, 106:13; 108:97 Triglyceride-rich lipoproteins, 108:209 Triglycerides, 105:419 Trophoblast, 108:235 Trophoblast cells, 105:217 Tubulin, 108:133 Tumor necrosis factor-a, 108:169 Ultrasound, 105:43 Umbilical cord, 108:121 Unfractionated heparin, 105:241; 106:31, 267; 107:235; 31:31 Unsaturated fat, 108:209 Urokinase, 105:263 Urokinase-type plasminogen activator (uPA), 107:169 Vmax maximal velocity, 106:71 Vaginal delivery, 105:15

Variability, 108:287 Vascular endothelial cell, 108:169 Vascular endothelial cells, 106:41 Vascular smooth muscle cells, 107:189 Vascular surgery, 106:285 VCAM-1, 108:107 Vein, 108:279 Venography, 105:477 Venous thromboembolism, 105:43. 371; 106:121; 107:7, 93, 287, 325; 108:97, 273 Venous thrombosis, 105:189; 106:265; 108:107 Venous Thrombosis, 107:109 Ventilation, 108:215 Vesicle aggregation, 108:175 Vitamin C, 106:143 Vitamin K epoxide reductase, 108:221 Vitamin K, 108:221 Vitamin K-dependent proteins, 108:221 Vitamins A and E, 105:277 von Willebrand disease, 105:135 von Willebrand factor (vWF), 105:471

371

von Willebrand factor, 105:25, 135, 519; 106:19, 127, 237; 108:121, 311 von Willebrand factor-cleaving protease (vWF-cp), 105:471 von Willebrand, 108:195 Wmax maximal work capacity, 105:481 Warfarin, 105:353; 107:39, 287; 108:25 Wettability gradient, 108:57 Whole blood, 107:209; 108:291 Wine phenolics, 106:205 Wistar– Kyoto rats (WKY), 105:507 WMSI wall motion score index, 105:37 Women, 105:481 X-Gal 5-bromo-4-chloro-3indonyl-h-D-galactoside, 11:365 Ximelagatran, 107:93, 163 ZK-807834, 105:347